The National Australian HCV Point-of-Care Testing Program
Launched by KIRBY INSTITUTE · Sep 6, 2021
Trial Information
Current as of April 30, 2025
Recruiting
Keywords
ClinConnect Summary
The National Australian HCV Point-of-Care Testing Program is a study aimed at improving the diagnosis and treatment of hepatitis C (HCV), a viral infection that can harm the liver. The researchers want to see if using a simple finger-stick test for HCV can help more people find out if they have the infection and get the necessary treatment. Participants will be recruited from places where people at risk for HCV go, such as drug treatment centers, homeless shelters, and prisons. During a single visit, participants will have a quick test to check for HCV and complete a short survey. If someone tests positive for the virus, they will be connected to standard care for treatment.
To join the study, participants need to be at least 18 years old and have a risk factor for HCV, such as a history of injecting drugs or having received blood products before 1990. People who are receiving services for those at risk—like in drug clinics or mental health facilities—can also participate. It's important to note that this study does not involve any treatment during the visit; it is focused solely on testing and gathering information. The goal is to help more people get diagnosed and treated for hepatitis C in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Provided informed consent.
- • 2. ≥ 18 years of age.
- • 3. Have a risk factor for the acquisition of HCV infection (including current or past injecting drug use, previous incarceration, HIV infection, receiving blood products prior to 1990, having a tattoo or piercing in an unregulated environment, a needle-stick injury, or a mother with HCV).
- OR:
- • 4. Are attending a service caring for people with risk factors for the acquisition of HCV infection (e.g. drug treatment clinics, needle and syringe programs, prisons, mobile outreach services, community health services, mental health services, and homelessness services).
- Exclusion Criteria:
- • a. Is unable or unwilling to provide informed consent or abide by the requirements of the study.
About Kirby Institute
The Kirby Institute is a leading research organization based at the University of New South Wales (UNSW) in Australia, dedicated to advancing global health through innovative clinical research, particularly in the fields of infectious diseases, HIV, and public health. With a strong emphasis on collaboration, the Institute conducts rigorous clinical trials and epidemiological studies, translating scientific findings into effective health policies and practices. Its multidisciplinary team of researchers, clinicians, and public health experts works to improve health outcomes and inform treatment strategies, making significant contributions to both local and international health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Footscray, Victoria, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Melbourne, Victoria, Australia
Sydney, New South Wales, Australia
Melbourne, Victoria, Australia
Bunbury, Western Australia, Australia
Canberra, Australian Capital Territory, Australia
Canberra, Australian Capital Territory, Australia
Bathurst, New South Wales, Australia
Port Macquarie, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Brisbane, Queensland, Australia
Brisbane, Queensland, Australia
Brisbane, Queensland, Australia
Cairns, Queensland, Australia
Inala, Queensland, Australia
Inala, Queensland, Australia
Ipswich, Queensland, Australia
Toowoomba, Queensland, Australia
Adelaide, South Australia, Australia
Adelaide, South Australia, Australia
Adelaide, South Australia, Australia
Adelaide, South Australia, Australia
Perth, Western Australia, Australia
Sydney, , Australia
Broken Hill, New South Wales, Australia
Coffs Harbour, New South Wales, Australia
Erina, New South Wales, Australia
Inverell, New South Wales, Australia
Lismore, New South Wales, Australia
Penrith, New South Wales, Australia
Quirindi, New South Wales, Australia
South Grafton, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Wagga Wagga, New South Wales, Australia
Waratah, New South Wales, Australia
Wollongong, New South Wales, Australia
Alice Springs, Northern Territory, Australia
Coorparoo, Queensland, Australia
Mount Gambier, South Australia, Australia
Murray Bridge, South Australia, Australia
Hobart, Tasmania, Australia
New Town, Tasmania, Australia
Perth, Western Australia, Australia
Perth, Western Australia, Australia
Perth, Western Australia, Australia
Perth, Western Australia, Australia
Perth, Western Australia, Australia
Broken Hill, New South Wales, Australia
Sydney, New South Wales, Australia
Melbourne, Victoria, Australia
Fremantle, Western Australia, Australia
Gosford, New South Wales, Australia
Ipswich, Queensland, Australia
Maroochydore, Queensland, Australia
Hackney, South Australia, Australia
Morwell, Victoria, Australia
Lismore, New South Wales, Australia
Brisbane, Queensland, Australia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials